首页 > 最新文献

Biochemia Medica最新文献

英文 中文
Designing and validating an autoverification system of biochemical test results in Hatay Mustafa Kemal University, clinical laboratory. 凯末尔大学临床实验室生化检测结果自动验证系统的设计与验证。
IF 3.3 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2022-10-01 Epub Date: 2022-08-05 DOI: 10.11613/BM.2022.030704
Bahar Ünlü Gül, Oğuzhan Özcan, Serdar Doğan, Abdullah Arpaci

Introduction: Autoverification (AV) is a postanalytical tool that uses algorithms to validate test results according to specified criteria. The Clinical and Laboratory Standard Institute (CLSI) document for AV of clinical laboratory test result (AUTO-10A) includes recommendations for laboratories needing guidance on implementation of AV algorithms. The aim was to design and validate the AV algorithm for biochemical tests.

Materials and methods: Criteria were defined according to AUTO-10A. Three different approaches for algorithm were used as result limit checks, which are reference range, reference range ± total allowable error, and 2nd and 98th percentile values. To validate the algorithm, 720 cases in middleware were tested. For actual cases, 3,188,095 results and 194,520 reports in laboratory information system (LIS) were evaluated using the AV system. Cohen's kappa (κ) was calculated to determine the degree of agreement between seven independent reviewers and the AV system.

Results: The AV passing rate was found between 77% and 85%. The highest rates of AV were in alanine transaminase (ALT), direct bilirubin (DBIL), and magnesium (Mg), which all had AV rates exceeding 85%. The most common reason for non-validated results was the result limit check (41%). A total of 328 reports evaluated by reviewers were compared to AV system. The statistical analysis resulted in a κ value between 0.39 and 0.63 (P < 0.001) and an agreement rate between 79% and 88%.

Conclusions: Our improved model can help laboratories design, build, and validate AV systems and be used as starting point for different test groups.

自动验证(AV)是一种后分析工具,它使用算法根据指定的标准验证测试结果。临床和实验室标准协会(CLSI)关于临床实验室检测结果AV (AUTO-10A)的文件包括对需要实施AV算法指导的实验室的建议。目的是设计和验证生物化学测试的AV算法。材料和方法:根据AUTO-10A标准确定标准。采用参考极差、参考极差±总允许误差、第2和第98百分位值三种不同的算法进行结果极限检查。为了验证算法的有效性,对中间件中的720个案例进行了测试。在实际病例中,使用AV系统对实验室信息系统(LIS)中的3188095份结果和194520份报告进行了评估。计算Cohen’s kappa (κ)以确定7位独立审稿人与AV系统之间的一致程度。结果:AV通过率为77% ~ 85%。谷丙转氨酶(ALT)、直接胆红素(DBIL)和镁(Mg)中AV率最高,均超过85%。未验证结果最常见的原因是结果限制检查(41%)。审稿人评估的328份报告与AV系统进行了比较。经统计学分析,κ值在0.39 ~ 0.63之间(P < 0.001),符合率在79% ~ 88%之间。结论:我们改进的模型可以帮助实验室设计、构建和验证AV系统,并可作为不同测试组的起点。
{"title":"Designing and validating an autoverification system of biochemical test results in Hatay Mustafa Kemal University, clinical laboratory.","authors":"Bahar Ünlü Gül,&nbsp;Oğuzhan Özcan,&nbsp;Serdar Doğan,&nbsp;Abdullah Arpaci","doi":"10.11613/BM.2022.030704","DOIUrl":"https://doi.org/10.11613/BM.2022.030704","url":null,"abstract":"<p><strong>Introduction: </strong>Autoverification (AV) is a postanalytical tool that uses algorithms to validate test results according to specified criteria. The Clinical and Laboratory Standard Institute (CLSI) document for AV of clinical laboratory test result (AUTO-10A) includes recommendations for laboratories needing guidance on implementation of AV algorithms. The aim was to design and validate the AV algorithm for biochemical tests.</p><p><strong>Materials and methods: </strong>Criteria were defined according to AUTO-10A. Three different approaches for algorithm were used as result limit checks, which are reference range, reference range <b>±</b> total allowable error, and 2nd and 98th percentile values. To validate the algorithm, 720 cases in middleware were tested. For actual cases, 3,188,095 results and 194,520 reports in laboratory information system (LIS) were evaluated using the AV system. Cohen's kappa (κ) was calculated to determine the degree of agreement between seven independent reviewers and the AV system.</p><p><strong>Results: </strong>The AV passing rate was found between 77% and 85%. The highest rates of AV were in alanine transaminase (ALT), direct bilirubin (DBIL), and magnesium (Mg), which all had AV rates exceeding 85%. The most common reason for non-validated results was the result limit check (41%). A total of 328 reports evaluated by reviewers were compared to AV system. The statistical analysis resulted in a κ value between 0.39 and 0.63 (P < 0.001) and an agreement rate between 79% and 88%.</p><p><strong>Conclusions: </strong>Our improved model can help laboratories design, build, and validate AV systems and be used as starting point for different test groups.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":" ","pages":"030704"},"PeriodicalIF":3.3,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40696905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bias, the unfinished symphony. 偏见,未完成的交响曲。
IF 3.3 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2022-10-01 DOI: 10.11613/BM.2022.030402
Abdurrahman Coşkun

In laboratory medicine, mathematical equations are frequently used to calculate various parameters including bias, imprecision, measurement uncertainty, sigma metric (SM), creatinine clearance, LDL-cholesterol concentration, etc. Mathematical equations have strict limitations and cannot be used in all situations and are not open to manipulations. Recently, a paper "Bias estimation for Sigma metric calculation: Arithmetic mean versus quadratic mean" was published in Biochemia Medica. In the paper, the author criticized the approach of taking the arithmetic mean of the multiple biases to obtain a single bias and proposed a quadratic method to estimate the overall bias using external quality assurance services (EQAS) data for SM calculation. This approach does not fit the purpose and it should be noted that using the correct equation in calculations is as important as using the correct reagent in the measurement of the analytes, therefore before using an equation, its suitability should be checked and confirmed.

在检验医学中,经常使用数学方程来计算各种参数,包括偏差、不精度、测量不确定度、西格玛度量(SM)、肌酐清除率、ldl -胆固醇浓度等。数学方程有严格的限制,不能在所有情况下使用,也不能被操纵。最近,在《生物化学医学》上发表了一篇题为《Sigma度量计算的偏倚估计:算术均值与二次均值》的论文。在本文中,作者批评了取多个偏差的算术平均值来获得单个偏差的方法,并提出了一种利用外部质量保证服务(EQAS)数据来估计SM计算总体偏差的二次方法。这种方法不符合目的,应该注意的是,在计算中使用正确的方程与在分析物的测量中使用正确的试剂同样重要,因此在使用方程之前,应检查和确认其适用性。
{"title":"Bias, the unfinished symphony.","authors":"Abdurrahman Coşkun","doi":"10.11613/BM.2022.030402","DOIUrl":"https://doi.org/10.11613/BM.2022.030402","url":null,"abstract":"<p><p>In laboratory medicine, mathematical equations are frequently used to calculate various parameters including bias, imprecision, measurement uncertainty, sigma metric (SM), creatinine clearance, LDL-cholesterol concentration, <i>etc</i>. Mathematical equations have strict limitations and cannot be used in all situations and are not open to manipulations. Recently, a paper \"Bias estimation for Sigma metric calculation: Arithmetic mean <i>versus</i> quadratic mean\" was published in Biochemia Medica. In the paper, the author criticized the approach of taking the arithmetic mean of the multiple biases to obtain a single bias and proposed a quadratic method to estimate the overall bias using external quality assurance services (EQAS) data for SM calculation. This approach does not fit the purpose and it should be noted that using the correct equation in calculations is as important as using the correct reagent in the measurement of the analytes, therefore before using an equation, its suitability should be checked and confirmed.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":"32 3","pages":"030402"},"PeriodicalIF":3.3,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9795249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Clinical importance of laboratory biomarkers in liver fibrosis. 实验室生物标志物在肝纤维化中的临床意义。
IF 3.3 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2022-10-01 DOI: 10.11613/BM.2022.030501
Goda Aleknavičiūtė-Valienė, Valdas Banys

Hepatic cirrhosis is a major health problem across the world, causing high morbidity and mortality. This disease has many etiologies, yet the result of chronic hepatic injury is hepatic fibrosis causing cirrhosis and hepatocellular carcinoma, as the liver's architecture is progressively destroyed. While liver biopsy is currently the gold standard for fibrosis staging, it has significant disadvantages, leading to a growing interest in non-invasive markers. Direct biomarkers - hyaluronic acid, laminin, collagen type III N-peptide, type IV collagen and cholylglycine - are new and rarely applied in routine clinical practice. This is the case primarily because there is no general consensus regarding the clinical application and effectiveness of the individual biomarkers. The usage of these markers in routine clinical practice could be advantageous for patients with liver fibrosis, requiring a simple blood test instead of a biopsy. The former option would be especially attractive for patients who are contraindicated for the latter. This review summarizes recent findings on direct biomarkers of liver fibrosis and highlights their possible applications and potential benefit for liver fibrosis diagnostics and/or staging.

肝硬化是世界范围内的一个主要健康问题,造成高发病率和死亡率。这种疾病有多种病因,但慢性肝损伤的结果是肝纤维化,导致肝硬化和肝细胞癌,因为肝脏的结构逐渐被破坏。虽然肝活检目前是纤维化分期的金标准,但它有明显的缺点,导致人们对非侵入性标志物的兴趣日益浓厚。透明质酸、层粘连蛋白、III型胶原n肽、IV型胶原和胆酰甘氨酸是新的直接生物标志物,在常规临床实践中很少应用。之所以会出现这种情况,主要是因为对于单个生物标志物的临床应用和有效性还没有达成普遍共识。在常规临床实践中使用这些标志物对肝纤维化患者可能是有利的,需要简单的血液检查而不是活检。前者对后者有禁忌症的患者尤其有吸引力。本文综述了肝纤维化直接生物标志物的最新发现,并强调了它们在肝纤维化诊断和/或分期中的可能应用和潜在益处。
{"title":"Clinical importance of laboratory biomarkers in liver fibrosis.","authors":"Goda Aleknavičiūtė-Valienė,&nbsp;Valdas Banys","doi":"10.11613/BM.2022.030501","DOIUrl":"https://doi.org/10.11613/BM.2022.030501","url":null,"abstract":"<p><p>Hepatic cirrhosis is a major health problem across the world, causing high morbidity and mortality. This disease has many etiologies, yet the result of chronic hepatic injury is hepatic fibrosis causing cirrhosis and hepatocellular carcinoma, as the liver's architecture is progressively destroyed. While liver biopsy is currently the gold standard for fibrosis staging, it has significant disadvantages, leading to a growing interest in non-invasive markers. Direct biomarkers - hyaluronic acid, laminin, collagen type III N-peptide, type IV collagen and cholylglycine - are new and rarely applied in routine clinical practice. This is the case primarily because there is no general consensus regarding the clinical application and effectiveness of the individual biomarkers. The usage of these markers in routine clinical practice could be advantageous for patients with liver fibrosis, requiring a simple blood test instead of a biopsy. The former option would be especially attractive for patients who are contraindicated for the latter. This review summarizes recent findings on direct biomarkers of liver fibrosis and highlights their possible applications and potential benefit for liver fibrosis diagnostics and/or staging.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":" ","pages":"030501"},"PeriodicalIF":3.3,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40655043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
A case of discrepant laboratory results in samples obtained from a central venous catheter and peripheral veins: when solving a pre-analytical mystery could improve patient care. 中心静脉导管和外周静脉样本实验室结果不一致一例:解决分析前的谜团可以改善患者护理。
IF 3.3 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2022-10-01 DOI: 10.11613/BM.2022.031001
Mattia Carini, Moira Micheletti, Giovanni Martellosio, Elisa Caravaggi, Nicola Portesi, Giorgio Biasiotto, Monica Marini, Duilio Brugnoni, Federico Serana

It is now generally accepted that laboratory errors or inaccurate results are mainly due to deficiencies in the pre-analytical phase. In this report, we describe the case of a 64-year-old male affected by a relapsing follicular lymphoma, who has been treated with chemotherapy through a central venous catheter (CVC). Four different samples were collected alternatively through peripheral venipuncture and CVC sampling. Unexpectedly, the samples collected from the two different sources showed contrasting results, with the presence of unusual macrophage-like cells in the samples obtained from CVC. It was later found that the CVC was displaced into the pleural space. This case report shows how the sampling process can sometimes influence test results and how it can help clinicians identify clinical conditions that have not yet manifested.

现在普遍认为,实验室错误或不准确的结果主要是由于分析前阶段的缺陷。在这个报告中,我们描述了一个64岁的男性患复发的滤泡性淋巴瘤,他通过中心静脉导管(CVC)接受化疗。通过外周静脉穿刺和CVC取样交替采集4种不同的样本。出乎意料的是,从两种不同来源收集的样本显示出截然不同的结果,从CVC获得的样本中存在异常的巨噬细胞样细胞。后来发现CVC移位到胸膜间隙。本病例报告显示了抽样过程有时如何影响检测结果,以及它如何帮助临床医生识别尚未表现出来的临床状况。
{"title":"A case of discrepant laboratory results in samples obtained from a central venous catheter and peripheral veins: when solving a pre-analytical mystery could improve patient care.","authors":"Mattia Carini,&nbsp;Moira Micheletti,&nbsp;Giovanni Martellosio,&nbsp;Elisa Caravaggi,&nbsp;Nicola Portesi,&nbsp;Giorgio Biasiotto,&nbsp;Monica Marini,&nbsp;Duilio Brugnoni,&nbsp;Federico Serana","doi":"10.11613/BM.2022.031001","DOIUrl":"https://doi.org/10.11613/BM.2022.031001","url":null,"abstract":"<p><p>It is now generally accepted that laboratory errors or inaccurate results are mainly due to deficiencies in the pre-analytical phase. In this report, we describe the case of a 64-year-old male affected by a relapsing follicular lymphoma, who has been treated with chemotherapy through a central venous catheter (CVC). Four different samples were collected alternatively through peripheral venipuncture and CVC sampling. Unexpectedly, the samples collected from the two different sources showed contrasting results, with the presence of unusual macrophage-like cells in the samples obtained from CVC. It was later found that the CVC was displaced into the pleural space. This case report shows how the sampling process can sometimes influence test results and how it can help clinicians identify clinical conditions that have not yet manifested.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":" ","pages":"031001"},"PeriodicalIF":3.3,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40655044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Laboratory policies and practices for thyroid function tests in Croatia: survey on behalf of Working Group for Laboratory Endocrinology of the Croatian Society of Medical Biochemistry and Laboratory Medicine. 克罗地亚甲状腺功能测试的实验室政策和做法:代表克罗地亚医学生物化学和实验室医学学会实验室内分泌学工作组进行的调查。
IF 3.3 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2022-10-01 Epub Date: 2022-08-05 DOI: 10.11613/BM.2022.030702
Adriana Bokulić, Ivana Zec, Sanja Goreta, Nora Nikolac Gabaj, Marija Kocijančić, Tihana Serdar Hiršl, Anamarija Đuras, Mateja Troha, Lada Stanišić, Daniela Šupe-Domić, Sanda Jelisavac Ćosić, Koraljka Đurić, Domagoj Marijančević, Marija Siter Kuprešanin, Iva Lukić, Alenka Pezo, Jasna Leniček Krleža

Introduction: Laboratory plays important part in screening, diagnosis, and management of thyroid disorders. The aim of this study was to estimate current laboratory preanalytical, analytical and postanalytical practices and policies in Croatia.

Materials and methods: Working Group for Laboratory Endocrinology of the Croatian Society of Medical Biochemistry and Laboratory Medicine designed a questionnaire with 27 questions and statements regarding practices and protocols in measuring thyroid function tests. The survey was sent to 111 medical biochemistry laboratories participating in external quality assurance scheme for thyroid hormones organized by Croatian Centre for Quality Assessment in Laboratory Medicine. Data is presented as absolute numbers and proportions.

Results: Fifty-three participants returned the questionnaire. Response rate varied depending on question, yielding a total survey response rate of 46-48%. All respondents perform thyroid stimulating hormone (TSH). From all other thyroid tests, most performed is free thyroxine (37/53) and least TSH-stimulating immunoglobulin (1/53). Laboratories are using nine different immunoassay methods. One tenth of laboratories is verifying manufacturer's declared limit of quantification for TSH and one third is verifying implemented reference intervals for all performed tests. Most of laboratories (91%) adopt the manufacturer's reference interval for adult population. Reference intervals for TSH are reported with different percentiles (90, 95 or 99 percentiles).

Conclusion: This survey showed current practices and policies in Croatian laboratories regarding thyroid testing. The results identified some critical spots and will serve as a foundation in creating national guidelines in order to harmonize laboratory procedures in thyroid testing in Croatia.

实验室在甲状腺疾病的筛查、诊断和治疗中起着重要的作用。这项研究的目的是估计克罗地亚目前的实验室分析前、分析后和分析后的做法和政策。材料和方法:克罗地亚医学生物化学和实验室医学学会实验室内分泌学工作组设计了一份问卷,其中有27个问题和关于测量甲状腺功能测试的做法和规程的说明。该调查已发送给参加克罗地亚实验室医学质量评估中心组织的甲状腺激素外部质量保证计划的111个医学生物化学实验室。数据以绝对数字和比例表示。结果:53名参与者进行了问卷调查。回应率因问题而异,总调查回应率为46-48%。所有应答者均进行促甲状腺激素(TSH)检测。在所有其他甲状腺检查中,检测游离甲状腺素最多(37/53),促tsh免疫球蛋白最少(1/53)。实验室正在使用九种不同的免疫测定方法。十分之一的实验室正在核实制造商所宣布的TSH定量限度,三分之一的实验室正在核实所有已进行的测试的实施参考区间。大多数实验室(91%)对成年人群采用制造商的参考区间。TSH的参考区间以不同的百分位数(90,95或99百分位数)报告。结论:这项调查显示了克罗地亚实验室关于甲状腺检测的现行做法和政策。结果确定了一些关键的点,并将作为制定国家准则的基础,以便在克罗地亚统一甲状腺检测的实验室程序。
{"title":"Laboratory policies and practices for thyroid function tests in Croatia: survey on behalf of Working Group for Laboratory Endocrinology of the Croatian Society of Medical Biochemistry and Laboratory Medicine.","authors":"Adriana Bokulić,&nbsp;Ivana Zec,&nbsp;Sanja Goreta,&nbsp;Nora Nikolac Gabaj,&nbsp;Marija Kocijančić,&nbsp;Tihana Serdar Hiršl,&nbsp;Anamarija Đuras,&nbsp;Mateja Troha,&nbsp;Lada Stanišić,&nbsp;Daniela Šupe-Domić,&nbsp;Sanda Jelisavac Ćosić,&nbsp;Koraljka Đurić,&nbsp;Domagoj Marijančević,&nbsp;Marija Siter Kuprešanin,&nbsp;Iva Lukić,&nbsp;Alenka Pezo,&nbsp;Jasna Leniček Krleža","doi":"10.11613/BM.2022.030702","DOIUrl":"https://doi.org/10.11613/BM.2022.030702","url":null,"abstract":"<p><strong>Introduction: </strong>Laboratory plays important part in screening, diagnosis, and management of thyroid disorders. The aim of this study was to estimate current laboratory preanalytical, analytical and postanalytical practices and policies in Croatia.</p><p><strong>Materials and methods: </strong>Working Group for Laboratory Endocrinology of the Croatian Society of Medical Biochemistry and Laboratory Medicine designed a questionnaire with 27 questions and statements regarding practices and protocols in measuring thyroid function tests. The survey was sent to 111 medical biochemistry laboratories participating in external quality assurance scheme for thyroid hormones organized by Croatian Centre for Quality Assessment in Laboratory Medicine. Data is presented as absolute numbers and proportions.</p><p><strong>Results: </strong>Fifty-three participants returned the questionnaire. Response rate varied depending on question, yielding a total survey response rate of 46-48%. All respondents perform thyroid stimulating hormone (TSH). From all other thyroid tests, most performed is free thyroxine (37/53) and least TSH-stimulating immunoglobulin (1/53). Laboratories are using nine different immunoassay methods. One tenth of laboratories is verifying manufacturer's declared limit of quantification for TSH and one third is verifying implemented reference intervals for all performed tests. Most of laboratories (91%) adopt the manufacturer's reference interval for adult population. Reference intervals for TSH are reported with different percentiles (90, 95 or 99 percentiles).</p><p><strong>Conclusion: </strong>This survey showed current practices and policies in Croatian laboratories regarding thyroid testing. The results identified some critical spots and will serve as a foundation in creating national guidelines in order to harmonize laboratory procedures in thyroid testing in Croatia.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":" ","pages":"030702"},"PeriodicalIF":3.3,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40697870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel approach for more precise quantification of M-protein using variables derived from immunosubtraction electropherogram and associated biochemistry analytes. 一种新的方法,更精确地定量m蛋白使用变量从免疫减去电泳和相关的生化分析。
IF 3.3 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2022-10-01 DOI: 10.11613/BM.2022.030703
Dragana Šegulja, Danica Matišić, Karmela Barišić, Dunja Rogić

Introduction: Due to limitations in currently used methodologies, the widely acknowledged approach for quantifying M-protein (MP) is not available. If employed as a source of quantitative data, the immunosubtraction electropherogram (IS-EPG), a qualitative analysis of MP, has the potential to overcome known analytical issues. The aim of this study is to explore measured and derived variables obtained from immunosubtraction electropherogram as a tool for quantifying MP and to compare the derived results to currently available methods.

Materials and methods: Measurands were amplitudes of MP and albumin fractions. Assessed derived variables included also immunoglobulin (Ig) G, IgA, IgM and total protein data. Capillary electrophoresis was used for determination of MP (in % of total protein concentration, or concentration of MP in g/L) by perpendicular drop and tangent skimming method.

Results: Passing-Bablok analysis showed the most comparable results in D1Ig and D1nIg variables, and the largest discrepancies in AD1nIg and AD2nIg variables. The background presence had greater impact on D1nIg comparison results than did on D1Ig results. The contribution of albumin fraction data did not improve the comparability of the results. The coefficients of variation of derived variables were lower (maximum 3.1%) than those obtained by densitometric measurements, regardless of MP concentration, polyclonal background, or migration pattern (2.3-37.7%).

Conclusion: The amplitude of MP spike in IS-EPG is an valuable measurand to compute derived variables for quantifying MP. The most comparable results were achieved with the D1Ig variable. Patients with monoclonal gammopathy can benefit from increased precision employing an objective and background independent measurand, especially during longitudinal follow-up.

由于目前使用的方法的局限性,广泛认可的定量m蛋白(MP)的方法是不可用的。如果用作定量数据的来源,免疫减法电泳(IS-EPG), MP的定性分析,有可能克服已知的分析问题。本研究的目的是探索从免疫减影电泳作为定量MP的工具获得的测量和衍生变量,并将衍生结果与目前可用的方法进行比较。材料和方法:测定MP和白蛋白组分的振幅。评估的衍生变量还包括免疫球蛋白(Ig) G、IgA、IgM和总蛋白数据。毛细管电泳(以总蛋白浓度%计,或以g/L计)采用垂直滴法和切线脱脂法测定。结果:passingbablok分析显示,D1Ig和D1nIg变量的结果最具可比性,而AD1nIg和AD2nIg变量的差异最大。背景存在对D1Ig比较结果的影响大于对D1Ig结果的影响。白蛋白分数数据的贡献并没有提高结果的可比性。无论MP浓度、多克隆背景或迁移模式如何,衍生变量的变异系数(最大3.1%)都低于密度测定法(2.3-37.7%)。结论:is - epg中MP峰幅值是定量计算MP衍生变量的一个有价值的指标。最具可比性的结果是用D1Ig变量获得的。单克隆伽玛病患者可以受益于使用客观和背景独立的测量提高精度,特别是在纵向随访期间。
{"title":"A novel approach for more precise quantification of M-protein using variables derived from immunosubtraction electropherogram and associated biochemistry analytes.","authors":"Dragana Šegulja,&nbsp;Danica Matišić,&nbsp;Karmela Barišić,&nbsp;Dunja Rogić","doi":"10.11613/BM.2022.030703","DOIUrl":"https://doi.org/10.11613/BM.2022.030703","url":null,"abstract":"<p><strong>Introduction: </strong>Due to limitations in currently used methodologies, the widely acknowledged approach for quantifying M-protein (MP) is not available. If employed as a source of quantitative data, the immunosubtraction electropherogram (IS-EPG), a qualitative analysis of MP, has the potential to overcome known analytical issues. The aim of this study is to explore measured and derived variables obtained from immunosubtraction electropherogram as a tool for quantifying MP and to compare the derived results to currently available methods.</p><p><strong>Materials and methods: </strong>Measurands were amplitudes of MP and albumin fractions. Assessed derived variables included also immunoglobulin (Ig) G, IgA, IgM and total protein data. Capillary electrophoresis was used for determination of MP (in % of total protein concentration, or concentration of MP in g/L) by perpendicular drop and tangent skimming method.</p><p><strong>Results: </strong>Passing-Bablok analysis showed the most comparable results in D1Ig and D1nIg variables, and the largest discrepancies in AD1nIg and AD2nIg variables. The background presence had greater impact on D1nIg comparison results than did on D1Ig results. The contribution of albumin fraction data did not improve the comparability of the results. The coefficients of variation of derived variables were lower (maximum 3.1%) than those obtained by densitometric measurements, regardless of MP concentration, polyclonal background, or migration pattern (2.3-37.7%).</p><p><strong>Conclusion: </strong>The amplitude of MP spike in IS-EPG is an valuable measurand to compute derived variables for quantifying MP. The most comparable results were achieved with the D1Ig variable. Patients with monoclonal gammopathy can benefit from increased precision employing an objective and background independent measurand, especially during longitudinal follow-up.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":"32 3","pages":"030701"},"PeriodicalIF":3.3,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9284078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bias estimation for Sigma metric calculation: arithmetic mean versus quadratic mean. 西格玛度量计算的偏差估计:算术平均值与二次平均值。
IF 3.3 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2022-10-01 Epub Date: 2022-08-05 DOI: 10.11613/BM.2022.030401
Şerif Ercan
The acquired hemophilia A (AHA) is a life-threatening condition. The incidence of AHA is extremely low, which requires a multidisciplinary approach to diagnosis and treatment. This is case report of 73-year-old man who presented with AHA secondary to severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) pneumonia. The patient had extensive skin bleeding and hematomas. In the coagulation screening tests activated partial thromboplastin time (APTT) was prolonged with normal prothrombin time (PT), which was indication for further investigation. The APTT in a mixing study with normal plasma did not correct so clotting factors inhibitors were suspected. With signs of bleeding, extremely low factor VIII (FVIII) activity (2 %) and presence of FVIII inhibitors, AHA was diagnosed and treatment initiated. Patient was treated with factor eight inhibitor bypassing agent (FEIBA) for three days, followed by long-term corticosteroid and cyclophosphamide therapy. Malignant and autoimmune diseases as the most common causes of AHA were ruled out. The patient had a good response to therapy with gradual normalization of APTT and FVIII activity. To the best of our knowledge, the present case is the first reported case of de novo AHA after SARS-CoV-2 pneumonia. The diagnosis of AHA should be suspected in a patient with bleeding into the skin and mucous membranes without a previous personal and family history of bleeding, and with isolated prolonged APTT. It is important to investigate any isolated prolongation of APTT in cooperation with clinical laboratory
{"title":"Bias estimation for Sigma metric calculation: arithmetic mean <i>versus</i> quadratic mean.","authors":"Şerif Ercan","doi":"10.11613/BM.2022.030401","DOIUrl":"https://doi.org/10.11613/BM.2022.030401","url":null,"abstract":"The acquired hemophilia A (AHA) is a life-threatening condition. The incidence of AHA is extremely low, which requires a multidisciplinary approach to diagnosis and treatment. This is case report of 73-year-old man who presented with AHA secondary to severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) pneumonia. The patient had extensive skin bleeding and hematomas. In the coagulation screening tests activated partial thromboplastin time (APTT) was prolonged with normal prothrombin time (PT), which was indication for further investigation. The APTT in a mixing study with normal plasma did not correct so clotting factors inhibitors were suspected. With signs of bleeding, extremely low factor VIII (FVIII) activity (2 %) and presence of FVIII inhibitors, AHA was diagnosed and treatment initiated. Patient was treated with factor eight inhibitor bypassing agent (FEIBA) for three days, followed by long-term corticosteroid and cyclophosphamide therapy. Malignant and autoimmune diseases as the most common causes of AHA were ruled out. The patient had a good response to therapy with gradual normalization of APTT and FVIII activity. To the best of our knowledge, the present case is the first reported case of de novo AHA after SARS-CoV-2 pneumonia. The diagnosis of AHA should be suspected in a patient with bleeding into the skin and mucous membranes without a previous personal and family history of bleeding, and with isolated prolonged APTT. It is important to investigate any isolated prolongation of APTT in cooperation with clinical laboratory","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":" ","pages":"030401"},"PeriodicalIF":3.3,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40696904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Acquired hemophilia A secondary to SARS-CoV-2 pneumonia: a case report. 获得性血友病A继发于SARS-CoV-2肺炎1例
IF 3.3 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2022-10-01 DOI: 10.11613/BM.2022.030801
Brkić Nikolina, Milić Marija, Bekavac Marija, Marković Maja, Perković Dubravka

The acquired hemophilia A (AHA) is a life-threatening condition. The incidence of AHA is extremely low, which requires a multidisciplinary approach to diagnosis and treatment. This is case report of 73-year-old man who presented with AHA secondary to severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) pneumonia. The patient had extensive skin bleeding and hematomas. In the coagulation screening tests activated partial thromboplastin time (APTT) was prolonged with normal prothrombin time (PT), which was indication for further investigation. The APTT in a mixing study with normal plasma did not correct so clotting factors inhibitors were suspected. With signs of bleeding, extremely low factor VIII (FVIII) activity (2%) and presence of FVIII inhibitors, AHA was diagnosed and treatment initiated. Patient was treated with factor eight inhibitor bypassing agent (FEIBA) for three days, followed by long-term corticosteroid and cyclophosphamide therapy. Malignant and autoimmune diseases as the most common causes of AHA were ruled out. The patient had a good response to therapy with gradual normalization of APTT and FVIII activity. To the best of our knowledge, the present case is the first reported case of de novo AHA after SARS-CoV-2 pneumonia. The diagnosis of AHA should be suspected in a patient with bleeding into the skin and mucous membranes without a previous personal and family history of bleeding, and with isolated prolonged APTT. It is important to investigate any isolated prolongation of APTT in cooperation with clinical laboratory experts.

获得性血友病A (AHA)是一种危及生命的疾病。AHA的发病率极低,需要多学科的诊断和治疗方法。这是一例73岁男性病例报告,他表现为继发于严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)肺炎的AHA。病人有广泛的皮肤出血和血肿。在凝血筛选试验中,活化的部分凝血活酶时间(APTT)与正常凝血酶原时间(PT)相比延长,这是进一步研究的指征。在与正常血浆的混合研究中,APTT不正确,因此怀疑是凝血因子抑制剂。随着出血的迹象,极低的因子VIII (FVIII)活性(2%)和FVIII抑制剂的存在,诊断为AHA并开始治疗。患者接受因子8抑制剂旁路剂(FEIBA)治疗3天,随后长期皮质类固醇和环磷酰胺治疗。排除了恶性和自身免疫性疾病是AHA最常见的病因。患者对治疗反应良好,APTT和FVIII活性逐渐正常化。据我们所知,本病例是第一例报道的SARS-CoV-2肺炎后新发AHA病例。如果患者有皮肤和粘膜出血,且没有个人和家族出血史,且有孤立的APTT,则应怀疑AHA的诊断。与临床实验室专家合作,调查任何孤立的APTT延长是很重要的。
{"title":"Acquired hemophilia A secondary to SARS-CoV-2 pneumonia: a case report.","authors":"Brkić Nikolina,&nbsp;Milić Marija,&nbsp;Bekavac Marija,&nbsp;Marković Maja,&nbsp;Perković Dubravka","doi":"10.11613/BM.2022.030801","DOIUrl":"https://doi.org/10.11613/BM.2022.030801","url":null,"abstract":"<p><p>The acquired hemophilia A (AHA) is a life-threatening condition. The incidence of AHA is extremely low, which requires a multidisciplinary approach to diagnosis and treatment. This is case report of 73-year-old man who presented with AHA secondary to severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) pneumonia. The patient had extensive skin bleeding and hematomas. In the coagulation screening tests activated partial thromboplastin time (APTT) was prolonged with normal prothrombin time (PT), which was indication for further investigation. The APTT in a mixing study with normal plasma did not correct so clotting factors inhibitors were suspected. With signs of bleeding, extremely low factor VIII (FVIII) activity (2%) and presence of FVIII inhibitors, AHA was diagnosed and treatment initiated. Patient was treated with factor eight inhibitor bypassing agent (FEIBA) for three days, followed by long-term corticosteroid and cyclophosphamide therapy. Malignant and autoimmune diseases as the most common causes of AHA were ruled out. The patient had a good response to therapy with gradual normalization of APTT and FVIII activity. To the best of our knowledge, the present case is the first reported case of <i>de novo</i> AHA after SARS-CoV-2 pneumonia. The diagnosis of AHA should be suspected in a patient with bleeding into the skin and mucous membranes without a previous personal and family history of bleeding, and with isolated prolonged APTT. It is important to investigate any isolated prolongation of APTT in cooperation with clinical laboratory experts.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":"32 3","pages":"030801"},"PeriodicalIF":3.3,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9279042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Evaluation of preanalytical and postanalytical phases in clinical biochemistry laboratory according to IFCC laboratory errors and patient safety specifications. 根据IFCC实验室错误和患者安全规范对临床生物化学实验室分析前和分析后阶段进行评估。
IF 3.3 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2022-10-01 DOI: 10.11613/BM.2022.030701
Nergiz Zorbozan, Orçun Zorbozan

Introduction: The aim of the study was to determine the current state of laboratory's extra-analytical phase performance by calculating preanalytical and postanalytical phase quality indicators (QIs) and sigma values and to compare obtained data according to desired quality specifications and sigma values reported by The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Working Group - Laboratory errors and Patient Safety.

Materials and methods: Preanalytical and postanalytical phase data were obtained through laboratory information system. Rejected samples in preanalytical phase were grouped according to reasons for rejection and frequencies were calculated both monthly and for 2019. Sigma values were calculated according to "short term sigma" table.

Results: The number of rejected samples in laboratory was 643 out of 191,831 in 2019. Total preanalytical phase rejection frequency was 0.22%. According to the reasons for rejection, QIs and sigma values were: "Samples with excessive transportation time": 0.0036 and 5.47; "Samples collected in wrong container" 0.02 and 5.11. In December, QIs and sigma values were: "Samples with excessive transportation time": 0.01 and 5.34; "Samples collected in wrong container": 0.03 and 4.98. The postanalytical QIs and sigma values were: "Reports delivered outside the specified time": 0.34 and 4.21; "Turn around time of potassium": 56 minute and 3.84, respectively. There were no errors in "Critical values of inpatients and outpatients notified after a consensually agreed time".

Conclusions: Extra-analytical phase was evaluated by comparing it with the latest quality specifications and sigma values which will contribute to improving the quality of laboratory medicine.

本研究的目的是通过计算分析前和分析后阶段质量指标(QIs)和sigma值来确定实验室分析外阶段性能的现状,并根据国际临床化学和检验医学联合会(IFCC)实验室错误和患者安全工作组报告的期望质量规范和sigma值来比较获得的数据。材料和方法:通过实验室信息系统获取分析前和分析后的相数据。根据拒收原因对预分析阶段的拒收样本进行分组,并计算每月和2019年的拒收频率。Sigma值根据“短期Sigma”表计算。结果:2019年实验室拒收样品191831份,拒收样品643份。总分析前相抑制频率为0.22%。根据拒收原因,QIs和sigma值分别为:“运输时间过长的样品”分别为0.0036和5.47;“样品装错容器”0.02和5.11。12月的QIs和sigma值分别为:“运输时间过长的样本”分别为0.01和5.34;“样品装错容器”:0.03和4.98。分析后的QIs和sigma值分别为:“在规定时间外提交的报告”:0.34和4.21;“钾的周转时间”分别为56分钟和3.84分钟。在“住院病人和门诊病人在双方同意的时间后通知的临界值”中没有错误。结论:通过与最新质量规范和sigma值的比较,对分析外相进行评价,有助于提高检验医学质量。
{"title":"Evaluation of preanalytical and postanalytical phases in clinical biochemistry laboratory according to IFCC laboratory errors and patient safety specifications.","authors":"Nergiz Zorbozan,&nbsp;Orçun Zorbozan","doi":"10.11613/BM.2022.030701","DOIUrl":"https://doi.org/10.11613/BM.2022.030701","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study was to determine the current state of laboratory's extra-analytical phase performance by calculating preanalytical and postanalytical phase quality indicators (QIs) and sigma values and to compare obtained data according to desired quality specifications and sigma values reported by The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Working Group - Laboratory errors and Patient Safety.</p><p><strong>Materials and methods: </strong>Preanalytical and postanalytical phase data were obtained through laboratory information system. Rejected samples in preanalytical phase were grouped according to reasons for rejection and frequencies were calculated both monthly and for 2019. Sigma values were calculated according to \"short term sigma\" table.</p><p><strong>Results: </strong>The number of rejected samples in laboratory was 643 out of 191,831 in 2019. Total preanalytical phase rejection frequency was 0.22%. According to the reasons for rejection, QIs and sigma values were: \"Samples with excessive transportation time\": 0.0036 and 5.47; \"Samples collected in wrong container\" 0.02 and 5.11. In December, QIs and sigma values were: \"Samples with excessive transportation time\": 0.01 and 5.34; \"Samples collected in wrong container\": 0.03 and 4.98. The postanalytical QIs and sigma values were: \"Reports delivered outside the specified time\": 0.34 and 4.21; \"Turn around time of potassium\": 56 minute and 3.84, respectively. There were no errors in \"Critical values of inpatients and outpatients notified after a consensually agreed time\".</p><p><strong>Conclusions: </strong>Extra-analytical phase was evaluated by comparing it with the latest quality specifications and sigma values which will contribute to improving the quality of laboratory medicine.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":"32 3","pages":"030701"},"PeriodicalIF":3.3,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9279044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Circulatory cytokeratin 17, marginal zone B1 protein and leucine-rich α2-glycoprotein-1 as biomarkers for disease severity and fibrosis in systemic sclerosis patients. 循环细胞角蛋白17、边缘区B1蛋白和富含亮氨酸的α2糖蛋白-1作为系统性硬化症患者疾病严重程度和纤维化的生物标志物
IF 3.3 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2022-10-01 DOI: 10.11613/BM.2022.030707
Paul Bălănescu, Eugenia Bălănescu, Cristian Băicuș, Anca Bălănescu

Introduction: Systemic sclerosis (Ssc) is a multiorgan debilitating autoimmune disease that associates the triad: vascular involvement, tissue fibrosis and profound immune response alterations. Numerous previous studies focused on identification of candidate proteomic Ssc biomarkers using mass-spectrometry techniques and a large number of candidate Ssc biomarkers emerged. These biomarkers must firstly be confirmed in independent patient groups. The aim of the present study was to investigate the association of cytokeratin 17 (CK17), marginal zone B1 protein (MZB1) and leucine-rich α2-glycoprotein-1 (LRG1) with clinical and biological Ssc characteristics.

Material and methods: Serum CK17, MZB1 and LRG1 were assessed in samples of the available Ssc biobank comprising of samples from 53 Ssc patients and 26 matched age and gender controls.

Results: Circulatory CK17, LRG1 and MZB1 concentrations were increased in Ssc patients. Cytokeratin 17 is independently associated with Ssc disease activity. Patients with pulmonary fibrosis expressed higher LRG1 and MZB1 concentrations. Serum MZB1 concentrations were also associated with extensive skin fibrosis.

Conclusions: Serum CK17, MZB1 and LRG1 were confirmed biomarkers for Ssc. LRG1 seems a good biomarker for pulmonary fibrosis, while MZB1 is a good biomarker for extensive skin fibrosis. CK17 proved to be independently associated with Ssc disease severity, higher CK17 values being protective for a more active disease.

简介:系统性硬化症(Ssc)是一种多器官衰弱性自身免疫性疾病,与血管受累、组织纤维化和深刻的免疫反应改变三要素有关。以往的大量研究集中在利用质谱技术鉴定候选蛋白质组学Ssc生物标志物上,并出现了大量候选Ssc生物标志物。这些生物标志物必须首先在独立的患者群体中得到证实。本研究旨在探讨细胞角蛋白17 (CK17)、边缘区B1蛋白(MZB1)和富含亮氨酸的α2糖蛋白-1 (LRG1)与Ssc临床和生物学特征的关系。材料和方法:血清CK17, MZB1和LRG1在现有Ssc生物库样本中进行评估,该样本包括53名Ssc患者和26名年龄和性别匹配的对照组。结果:Ssc患者循环CK17、LRG1和MZB1浓度升高。细胞角蛋白17与Ssc疾病活动性独立相关。肺纤维化患者表达更高的LRG1和MZB1浓度。血清MZB1浓度也与广泛的皮肤纤维化有关。结论:血清CK17、MZB1和LRG1是Ssc的生物标志物。LRG1似乎是肺纤维化的良好生物标志物,而MZB1是广泛皮肤纤维化的良好生物标志物。CK17被证明与Ssc疾病严重程度独立相关,较高的CK17值对更活跃的疾病有保护作用。
{"title":"Circulatory cytokeratin 17, marginal zone B1 protein and leucine-rich α2-glycoprotein-1 as biomarkers for disease severity and fibrosis in systemic sclerosis patients.","authors":"Paul Bălănescu,&nbsp;Eugenia Bălănescu,&nbsp;Cristian Băicuș,&nbsp;Anca Bălănescu","doi":"10.11613/BM.2022.030707","DOIUrl":"https://doi.org/10.11613/BM.2022.030707","url":null,"abstract":"<p><strong>Introduction: </strong>Systemic sclerosis (Ssc) is a multiorgan debilitating autoimmune disease that associates the triad: vascular involvement, tissue fibrosis and profound immune response alterations. Numerous previous studies focused on identification of candidate proteomic Ssc biomarkers using mass-spectrometry techniques and a large number of candidate Ssc biomarkers emerged. These biomarkers must firstly be confirmed in independent patient groups. The aim of the present study was to investigate the association of cytokeratin 17 (CK17), marginal zone B1 protein (MZB1) and leucine-rich α2-glycoprotein-1 (LRG1) with clinical and biological Ssc characteristics.</p><p><strong>Material and methods: </strong>Serum CK17, MZB1 and LRG1 were assessed in samples of the available Ssc biobank comprising of samples from 53 Ssc patients and 26 matched age and gender controls.</p><p><strong>Results: </strong>Circulatory CK17, LRG1 and MZB1 concentrations were increased in Ssc patients. Cytokeratin 17 is independently associated with Ssc disease activity. Patients with pulmonary fibrosis expressed higher LRG1 and MZB1 concentrations. Serum MZB1 concentrations were also associated with extensive skin fibrosis.</p><p><strong>Conclusions: </strong>Serum CK17, MZB1 and LRG1 were confirmed biomarkers for Ssc. LRG1 seems a good biomarker for pulmonary fibrosis, while MZB1 is a good biomarker for extensive skin fibrosis. CK17 proved to be independently associated with Ssc disease severity, higher CK17 values being protective for a more active disease.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":" ","pages":"030707"},"PeriodicalIF":3.3,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40655045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Biochemia Medica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1